Moclobemide treatment of clozapine-induced hypersalivation: Pilot open
study
Clinical Neuropharmacology,
Kreinin A et al. – Findings suggest that moclobemide can be another additional and safe medication for treatment of clozapine-induced hypersalivation (CIHS), pending more data based on controlled studies.
Methods
- Study of moclobemide, a reversible monoamine oxidase inhibitor-A, as an additional possibility for controlling or at least minimizing CIHS
- Subjects: 14 pts with schizophrenia who had CIHS
- Moclobemide (150-300 mg/d) added to conventional regular treatment during 14 days
- Assessment of hypersalivation at treatment start and at endpoint by 5-point Nocturnal Hypersalivation Rating Scale
Results
- Beneficial effect after addition of moclobemide: two thirds of pts with CIHS
- Nonresponders: one-third of pts
- No adverse effects for any p
No comments:
Post a Comment